EA202192237A1 - Кристаллические формы ингибитора jak2 - Google Patents

Кристаллические формы ингибитора jak2

Info

Publication number
EA202192237A1
EA202192237A1 EA202192237A EA202192237A EA202192237A1 EA 202192237 A1 EA202192237 A1 EA 202192237A1 EA 202192237 A EA202192237 A EA 202192237A EA 202192237 A EA202192237 A EA 202192237A EA 202192237 A1 EA202192237 A1 EA 202192237A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline forms
jak2 inhibitor
jak2
inhibitor
compositions
Prior art date
Application number
EA202192237A
Other languages
English (en)
Russian (ru)
Inventor
Бенуа Роберт
Паскаль Биллот
Original Assignee
Импэкт Биомедисинс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Импэкт Биомедисинс, Инк. filed Critical Импэкт Биомедисинс, Инк.
Publication of EA202192237A1 publication Critical patent/EA202192237A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202192237A 2019-02-12 2020-02-11 Кристаллические формы ингибитора jak2 EA202192237A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1902018A FR3092581A1 (fr) 2019-02-12 2019-02-12 Formes cristallines d'un inhibiteur de jak2
PCT/US2020/017764 WO2020167844A1 (en) 2019-02-12 2020-02-11 Crystalline forms of a jak2 inhibitor

Publications (1)

Publication Number Publication Date
EA202192237A1 true EA202192237A1 (ru) 2021-12-14

Family

ID=68281482

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192237A EA202192237A1 (ru) 2019-02-12 2020-02-11 Кристаллические формы ингибитора jak2

Country Status (13)

Country Link
US (1) US20220332706A1 (https=)
EP (1) EP3927704A4 (https=)
JP (2) JP2022520083A (https=)
KR (1) KR20210148110A (https=)
CN (1) CN114026088A (https=)
AU (1) AU2020221796A1 (https=)
BR (1) BR112021015318A2 (https=)
EA (1) EA202192237A1 (https=)
FR (1) FR3092581A1 (https=)
IL (1) IL285427A (https=)
MX (1) MX2021009423A (https=)
SG (1) SG11202108607QA (https=)
WO (1) WO2020167844A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
US12559463B2 (en) * 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
TW201316989A (zh) * 2011-07-21 2013-05-01 Sanofi Sa 用於治療真性多血症及原發性血小板過多症之組合物及方法
US10040804B2 (en) * 2016-12-21 2018-08-07 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Also Published As

Publication number Publication date
CN114026088A (zh) 2022-02-08
SG11202108607QA (en) 2021-09-29
JP2022520083A (ja) 2022-03-28
BR112021015318A2 (pt) 2021-10-05
WO2020167844A1 (en) 2020-08-20
JP2025032217A (ja) 2025-03-11
FR3092581A1 (fr) 2020-08-14
MX2021009423A (es) 2021-11-17
AU2020221796A1 (en) 2021-08-12
IL285427A (en) 2021-09-30
KR20210148110A (ko) 2021-12-07
EP3927704A4 (en) 2022-12-28
US20220332706A1 (en) 2022-10-20
EP3927704A1 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
PH12021553018A1 (en) New egfr inhibitors
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
PH12021500013A1 (en) New heterocyclic compounds as monoacylgylcerol lipase inhibitors
PH12022551524A1 (en) Irak degraders and uses thereof
WO2020243415A3 (en) Tead inhibitors and uses thereof
PH12022551503A1 (en) Kras mutant protein inhibitors
MY209340A (en) Egfr inhibitor for the treatment of cancer
PH12021500026A1 (en) Irak degraders and uses thereof
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
PH12022551522A1 (en) Smarca degraders and uses thereof
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
MX2021003425A (es) Formas morficas de los inhibidores del factor d del complemento.
MX2024008964A (es) Analogos de rapamicina y usos de los mismos.
EA201890256A1 (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
MX2022002443A (es) Compuestos inhibidores de perk.
BR112022005895A2 (pt) Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2
MX2022000243A (es) Nuevos compuestos heterociclicos.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.